IDEX CORP /DE/ (IEX) Earnings History

IDEX CORP /DE/ - Q4 FY2025 EarningsBeat

Filed at: Feb 4, 2026, 7:00 AM EST|Read from source

EXECUTIVE SUMMARY

IDEX Corporation reported a solid finish to 2025 with record fourth-quarter sales and orders, driven by strength in its Health & Science Technologies segment, particularly in AI-related applications. While full-year sales showed modest growth, the company navigated a challenging demand environment in other segments, focusing on operational efficiencies and strategic platform growth.

POSITIVE HIGHLIGHTS

  • •

    Record fourth quarter net sales of $899 million increased 4% on a reported basis and 1% organically.

    positive
  • •

    Record fourth quarter orders of $979 million increased 20% on a reported basis and 16% organically, driven by strength in HST.

    positive
  • •

    Full year operating cash flow of $680 million increased 2% and was 141% of net income, up from 132% in the prior year.

    positive
  • •

    Full year free cash flow of $617 million increased 2% and yielded conversion of 103%, up from 101%.

    positive

CONCERNS & RISKS

  • •

    Full year reported diluted EPS decreased 3% to $6.41, reflecting higher operating results offset by increased depreciation, amortization, restructuring costs, interest expense, and taxes.

    negative
  • •

    Volumes were lower in the Fluid & Metering Technologies (FMT) and Fire & Safety/Diversified Products (FSDP) segments, partially offset by higher volumes in HST.

    attention
  • •

    Full year organic sales increased only 1%, indicating a slowdown from prior year growth.

    attention
  • •

    The effective tax rate increased due to legislation enacted in 2025, impacting foreign sourced income and state income taxes.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$899.10M
+4.2%
Prior year: $862.90M
Annual (YTD)
$3.46B
N/A
Prior year: $3.27B
Net Income
Quarterly
$128.30M
N/A
EPS (Diluted)
Quarterly
$1.71
+5.6%
Prior year: $1.62
Annual (YTD)
$6.41
N/A
Prior year: $6.64
Operating Income
Quarterly
$183.60M
N/A
EPS (Basic)
Quarterly
N/A
N/A

MARGIN ANALYSIS

Gross Margin
Current Quarter
43.1%
Prior Year
42.5%
YoY Change
+60 bps
Operating Margin
Current Quarter
20.4%
Prior Year
19.2%
YoY Change
+126 bps
Net Margin
Current Quarter
14.3%
Prior Year
14.3%
YoY Change
-1 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

REVENUE BY SEGMENT — Q4 FY2025 2025

VISUAL OVERVIEW

|
Health & Science Technologies
0.0%
N/A
CC: +5.0%
Fluid & Metering Technologies
0.0%
N/A
CC: +1.0%
Fire & Safety/Diversified Products
0.0%
N/A
CC: -5.0%

DETAILED BREAKDOWN

|
SegmentCurrentPrior YrYoY% TotalCC
Health & Science Technologies
N/A———+5.0%
Fluid & Metering Technologies
N/A———+1.0%
Fire & Safety/Diversified Products
N/A———-5.0%
Total Revenue$0.00M——100.0%—

Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.

MANAGEMENT GUIDANCE

FY2026

organic sales
$1.0M—$2.0M
Mid-point: $1.5M
"increase 1% to 2% over the prior year"
adjusted diluted EPS
$8.15—$8.35
Mid-point: $8.25

Q1 2026

organic sales
$1.0M—$1.0M
Mid-point: $1.0M
"increase approximately 1% from the prior year period"
adjusted diluted EPS
$1.73—$1.78
Mid-point: $1.75

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

MANAGEMENT COMMENTARY

Order growth in HST segment built momentum in the fourth quarter from increasing demand for AI-related projects.

— IDEX CORP /DE/, Q4 FY2025 2025 Earnings Call

Businesses in FMT and FSDP segments are aggressively managing all the factors in their control in a challenging demand environment.

— IDEX CORP /DE/, Q4 FY2025 2025 Earnings Call

Committed to executing strategy of building focused growth platforms that leverage differentiated capabilities.

— IDEX CORP /DE/, Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.